<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Butenafine: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Butenafine: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Butenafine: Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="11573" href="/d/html/11573.html" rel="external">see "Butenafine: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F143754"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Lotrimin Ultra [OTC];</li>
<li>Mentax [DSC]</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F143766"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Antifungal Agent, Topical</li></ul></div>
<div class="block doa drugH1Div" id="F143755"><span class="drugH1">Dosing: Adult</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="15c0a5bc-b04b-4bce-808a-eba28afcd673">Tinea infections</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Tinea infections:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Tinea corporis/tinea cruris:</i>
<b>Topical:</b> Cream 1%: Apply to affected and surrounding area(s) once daily until clinical resolution, typically 1 to 3 weeks (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Goldstein.1','lexi-content-ref-25294700','lexi-content-ref-12046779','lexi-content-ref-manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Goldstein.1','lexi-content-ref-25294700','lexi-content-ref-12046779','lexi-content-ref-manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Tinea pedis (labeled use)/tinea manuum (off-label use):</i>
<b>Topical:</b> Cream 1%: Apply to affected and surrounding area(s) once or twice daily until 1 week after clinical resolution, typically for 2 weeks (twice daily) or 4 weeks (once daily) total (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-9039200','lexi-content-ref-9039199','lexi-content-ref-12046779','lexi-content-ref-manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-9039200','lexi-content-ref-9039199','lexi-content-ref-12046779','lexi-content-ref-manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Tinea versicolor (pityriasis versicolor):</i>
<b>Topical:</b> Cream 1%: Apply to affected area(s) and immediate surrounding skin once daily for 2 weeks (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12432425','lexi-content-ref-manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12432425','lexi-content-ref-manu.1'])">Ref</a></span>).</p></div>
</div>
</div>
<div class="block dora drugH1Div" id="F50991766"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer’s labeling. However, dosage adjustment unlikely due to low systemic absorption.</p></div>
<div class="block doha drugH1Div" id="F50989040"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer’s labeling. However, dosage adjustment unlikely due to low systemic absorption.</p></div>
<div class="block doe drugH1Div" id="F143756"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing.</p></div>
<div class="block dop drugH1Div" id="F143762"><span class="drugH1">Dosing: Pediatric</span>
<p style="text-indent:0em;display:inline">Children ≥12 years and Adolescents: Refer to adult dosing.</p></div>
<div class="block dorp drugH1Div" id="F51084043"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer’s labeling. However, dosage adjustment unlikely due to low systemic absorption.</p></div>
<div class="block dohp drugH1Div" id="F51084044"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer’s labeling. However, dosage adjustment unlikely due to low systemic absorption.</p></div>
<div class="block adr drugH1Div" id="F143734"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">≥1%: Dermatologic: Burning sensation of skin, contact dermatitis, erythema, pruritus, skin irritation, stinging of the skin</p></div>
<div class="block coi drugH1Div" id="F143744"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">Hypersensitivity to butenafine or any component of the formulation</p>
<p style="text-indent:-2em;margin-left:2em;">OTC labeling: When used for self-medication, do not use on nails or scalp, in or near the mouth or eyes, or for vaginal yeast infections</p></div>
<div class="block war drugH1Div" id="F143731"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">• Allylamine antifungal hypersensitivity: Use caution in patients sensitive to allylamine antifungals (eg naftifine, terbinafine); cross sensitivity to butenafine may exist.</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">• Irritation: Discontinue if sensitivity or irritation occurs.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>
<i>Special populations:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">• Immunocompromised patients: Has not been studied in immunocompromised patients.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">• Appropriate use: For external use only; avoid contact with eyes, mouth, nose, or other mucous membranes.</p></div>
<div class="block foc drugH1Div" id="F143740"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Cream, External, as hydrochloride: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Lotrimin Ultra: 1% (12 g, 30 g [DSC]) [contains benzyl alcohol, cetyl alcohol, propylene glycol, sodium benzoate, trolamine (triethanolamine)]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Mentax: 1% (15 g [DSC], 30 g [DSC]) [contains benzyl alcohol, sodium benzoate]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 1% (12 g, 30 g)</p></div>
<div class="block geq drugH1Div" id="F143727"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block fee drugH1Div" id="F143746"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Cream</b> (Butenafine HCl External)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">1% (per gram): $0.67</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Cream</b> (Lotrimin Ultra External)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">1% (per gram): $0.90</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block adm drugH1Div" id="F5194003"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Topical:</b> For external use only; avoid contact with eyes, mouth, nose, or other mucous membranes. Apply to clean, dry skin. Avoid occlusive dressings.</p>
<p style="text-indent:-2em;margin-left:2em;">Tinea pedis: Wear well-fitted, ventilated shoes; change socks and shoes at least once daily.</p></div>
<div class="block admp drugH1Div" id="F52757041"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">Topical: For external use only; avoid contact with eyes, mouth, nose, or other mucous membranes. Apply to clean, dry skin. Avoid occlusive dressings. Wash hands after each use.</p></div>
<div class="block use drugH1Div" id="F143741"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Topical infections:</b> Topical treatment of tinea (pityriasis) versicolor due to <i>Malassezia furfur</i></p>
<p style="text-indent:-2em;margin-left:2em;">
<b>OTC labeling:</b> Topical treatment of tinea pedis (athlete's foot), tinea cruris (jock itch), and tinea corporis (ringworm)</p></div>
<div class="block off-label drugH1Div" id="F56323993"><span class="drugH1">Use: Off-Label: Adult</span><p>Tinea manuum</p></div>
<div class="block mst drugH1Div" id="F143772"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues: </span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Lotrimin may be confused with Lotrisone</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F13298916"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F6218718"><span class="drugH1">Drug Interactions</span>
<br/><br/><div class="clear"></div><p style="text-indent:0em;display:inline">There are no known significant interactions.</p></div>
<div class="block pri drugH1Div" id="F5194002"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;display:inline">Adverse effects were not observed in animal reproduction studies.</p></div>
<div class="block brc drugH1Div" id="F16265708"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:0em;display:inline">It is not known if butenafine is excreted in breast milk. The manufacturer recommends that caution be exercised when administering butenafine to nursing women. </p></div>
<div class="block mop drugH1Div" id="F143738"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Culture and KOH exam, clinical signs of tinea pedis</p></div>
<div class="block pha drugH1Div" id="F143730"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Butenafine exerts fungicidal activity against dermatophytes (eg trichophyton, epidermophyton) by blocking squalene epoxidation, resulting in inhibition of ergosterol synthesis and subsequent weakening of fungal cell membranes.</p></div>
<div class="block phk drugH1Div" id="F143743"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Absorption: Minimal systemic </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Metabolism: Hepatic via hydroxylation </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Half-life elimination: Biphasic: Alpha: 35 hours; Beta: &gt;150 hours </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Time to peak, serum: 6 to 15 hours</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F5539825"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Butafyl</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Buticrem</span>;</li>
<li>
<span class="countryCode">(BD)</span> <span class="country">Bangladesh</span><span class="countrySeparator">: </span><span class="drugName">Butefin | Fintop | Tenafin</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Tefin</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Dermacom</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">Jia rui | Jie ning | Mai ke shu | Te li da</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Butemax</span>;</li>
<li>
<span class="countryCode">(DO)</span> <span class="country">Dominican Republic</span><span class="countrySeparator">: </span><span class="drugName">Butefin</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Fintop</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Mentax</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Butaximark | Fungestic | Mentax | Mycovrex | Tinearest</span>;</li>
<li>
<span class="countryCode">(ID)</span> <span class="country">Indonesia</span><span class="countrySeparator">: </span><span class="drugName">Dermax</span>;</li>
<li>
<span class="countryCode">(IL)</span> <span class="country">Israel</span><span class="countrySeparator">: </span><span class="drugName">Mentax</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Butenaskin | Butifun | Butop | Exebute | Fintop | Kutica</span>;</li>
<li>
<span class="countryCode">(JO)</span> <span class="country">Jordan</span><span class="countrySeparator">: </span><span class="drugName">Mentax</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Butenafine HCL | Butenarock | Lamaston mx | Mentax | Meridam | Scorba dash | Volley</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Butena | Butenil | Danafin | Mentax | Nanopin</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Mentax</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Mentax</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Derfina | Lexoderil</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Butenfit</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Butenafine HCL | Funcid</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Athlete's foot | Lotrimin ultra | Mentax</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Butafyl | Derfina</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Butafly | Butefin | Butegal</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Ankorme | Antimax | Benafine | Bunafine | Butederm | Butefine | Butemax | Emould | Mentax | Sanmasu | Sergen | Sumelo | Superin | Udaxen</span>;</li>
<li>
<span class="countryCode">(UG)</span> <span class="country">Uganda</span><span class="countrySeparator">: </span><span class="drugName">Fintop</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-Goldstein.1">
<a name="Goldstein.1"></a>Goldstein AO, Goldstein BG. Dermatophyte (tinea) infections. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed August 24, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9270509">
<a name="9270509"></a>Greer DL, Weiss J, Rodriguez DA, et al, “A Randomized Trial to Assess Once-Daily Topical Treatment of Tinea Corporis With Butenafine, a New Antifungal Agent,” <i>J Am Acad Dermatol</i>, 1997, 37(2 Pt 1):231-5.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/butenafine-drug-information/abstract-text/9270509/pubmed" id="9270509" target="_blank">9270509</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12432425">
<a name="12432425"></a>Gupta AK. Butenafine: an update of its use in superficial mycoses. <i>Skin Therapy Lett</i>. 2002;7(7):1-2, 5.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/butenafine-drug-information/abstract-text/12432425/pubmed" id="12432425" target="_blank">12432425</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18478357">
<a name="18478357"></a>Gupta AK, Cooper EA. Update in antifungal therapy of dermatophytosis. <i>Mycopathologia</i>. 2008;166(5-6):353-367. doi:10.1007/s11046-008-9109-0<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/butenafine-drug-information/abstract-text/18478357/pubmed" id="18478357" target="_blank">18478357</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Lotrimin Ultra (butenafine hydrochloride cream) [prescribing information]. Whippany, NJ: Bayer HealthCare LLC; received December 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9530545">
<a name="9530545"></a>McNeely W and Spencer CM, “Butenafine,” <i>Drugs</i>, 1998, 55(3):405-12.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/butenafine-drug-information/abstract-text/9530545/pubmed" id="9530545" target="_blank">9530545</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Mentax (butenafine hydrochloride cream) [prescribing information]. Morgantown, WV: Mylan Pharmaceuticals Inc; June 2018.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-manu.1">
<a name="manu.1"></a>Refer to manufacturer's labeling.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9646136">
<a name="9646136"></a>Reyes BA, Beutner KR, Cullen SI, et al, “Butenafine, a Fungicidal Benzylamine Derivative, Used Once Daily for the Treatment of Interdigital Tinea Pedis,” <i>Int J Dermatol</i>, 1998, 37(6):450-3.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/butenafine-drug-information/abstract-text/9646136/pubmed" id="9646136" target="_blank">9646136</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9039200">
<a name="9039200"></a>Savin R, De Villez RL, Elewski B, et al. One-week therapy with twice-daily butenafine 1% cream versus vehicle in the treatment of tinea pedis: a multicenter, double-blind trial. <i>J Am Acad Dermatol</i>. 1997;36(2, pt 1):S15-S19. doi:10.1016/s0190-9622(97)70317-7<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/butenafine-drug-information/abstract-text/9039200/pubmed" id="9039200" target="_blank">9039200</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9830263">
<a name="9830263"></a>Syed TA, Ahmadpour OA, Ahmad SA, et al, “Management of Toenail Onychomycosis With 2% Butenafine and 20% Urea Cream: A Placebo-Controlled, Double-Blind Study,” <i>J Dermatol</i>, 1998, 25(10):648-52.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/butenafine-drug-information/abstract-text/9830263/pubmed" id="9830263" target="_blank">9830263</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9217695">
<a name="9217695"></a>“Topical Butenafine for Tinea Pedis,” <i>Med Lett Drugs Ther</i>, 1997, 39(1004):63-64.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/butenafine-drug-information/abstract-text/9217695/pubmed" id="9217695" target="_blank">9217695</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9039199">
<a name="9039199"></a>Tschen E, Elewski B, Gorsulowsky DC, et al, “Treatment of Interdigital Tinea Pedis With a 4-Week Once-Daily Regimen of Butenafine Hydrochloride 1% Cream,” <i>J Am Acad Dermatol</i>, 1997, 36(2 Pt 1):S9-14.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/butenafine-drug-information/abstract-text/9039199/pubmed" id="9039199" target="_blank">9039199</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25294700">
<a name="25294700"></a>van Zuuren EJ, Fedorowicz Z, El-Gohary M. Evidence-based topical treatments for tinea cruris and tinea corporis: a summary of a Cochrane systematic review. <i>Br J Dermatol</i>. 2015;172(3):616-641. doi:10.1111/bjd.13441<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/butenafine-drug-information/abstract-text/25294700/pubmed" id="25294700" target="_blank">25294700</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12046779">
<a name="12046779"></a>Weinstein A, Berman B. Topical treatment of common superficial tinea infections. <i>Am Fam Physician</i>. 2002;65(10):2095-2102.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/butenafine-drug-information/abstract-text/12046779/pubmed" id="12046779" target="_blank">12046779</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 9177 Version 153.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
